Company & Sponsor Intelligence

ACADIA Pharmaceuticals Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials8

Recruiting0

Completed7

Countries1

Therapeutic footprint

autismdepressionother_neurologyparkinsons

Indexed studies

NCT03575052A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
other_neurology · United StatesPHASE3

NCT04292223Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
parkinsons · United StatesPHASE4

NCT05523895Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
autism · United StatesPHASE2, PHASE3

NCT00477672A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
parkinsons · United StatesPHASE3

NCT03018340Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
depression · United StatesPHASE2

NCT04164758Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
parkinsons · United StatesPHASE2

NCT01174004A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
parkinsons · United StatesPHASE3

NCT03482882Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
parkinsons · United StatesPHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →